Infective Endocarditis (IE)
Conditions
Keywords
Enterococcus faecalis, Bacteremia, Dysbiosis, Pathophysiology, Virulence factors
Brief summary
Enterococci are pathobionts of the human intestinal microbiota: they colonize the gastrointestinal tract as well as the skin, urine, wounds, bile, the oral cavity and endodontic canal, and medical devices (urinary catheters, venous catheters, etc.). They are responsible for urinary, dental, bloodstream, endocardial, biliary, and gastrointestinal infections. Enterococcus faecalis is the enterococcus most frequently isolated from clinical specimens. It is the third leading cause of infective endocarditis (infection of the cardiac valves) and the leading cause of endocarditis following TAVI (transcatheter aortic valve implantation via the femoral route). E. faecalis infective endocarditis (EFIE) is severe and difficult to treat, with a particularly high relapse rate despite appropriate antibiotic therapy. Cardiac valve contamination is always secondary to E. faecalis bacteremia, particularly in cases of isolated E. faecalis bacteremia (EFIB), defined by the absence of an identifiable portal of entry. Once in the bloodstream, the bacterium adheres to the valvular endothelium (healthy or damaged) through specific virulence factors, including endocarditis- and biofilm-associated pili (ebp), the collagen adhesin Ace, and aggregation substance (Agg). The classical portals of entry for EFIE are infections of the urinary tract and the gastrointestinal tract. However, despite extensive investigations, the source of infection remains unidentified in more than 50% of cases. An imbalance of the intestinal microbiota, leading to overgrowth and subsequent translocation of E. faecalis from the digestive tract into the bloodstream, could explain the absence of an identifiable portal of entry during routine clinical and paraclinical evaluations. This plausible hypothesis remains largely unexplored to date. A better understanding of the underlying pathophysiology-particularly gut dysbiosis and the pathogen's capacity for intestinal translocation-could improve the prevention of EFIE occurrence and relapse.
Interventions
BIOLOGICALMicrobiological sampling (swab collection)
Participants in the case group will undergo microbiological sampling consisting of four swabs: two rectal swabs, one oral swab, and one skin swab from the inguinal fold. Participants in the control group will undergo a single rectal swab. The samples will be collected for microbiological analysis.
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 years and older; * Capable of giving informed consent; * Affiliated with a social security system; * Hospitalized with at least one positive blood culture for Enterococcus faecalis, without an obvious clinical entry point after physical examination and initial routine investigations (BIEF group); * Hospitalized for another bacteremia, without an obvious clinical entry point after initial routine investigations (Control group); * Receiving antibiotic therapy that was started less than 48 hours ago
Exclusion criteria
* Refusal to participate in the study; * Pregnant or breastfeeding women; * Individuals under guardianship, curatorship, deprived of liberty, or under judicial protection; * Antibiotic therapy for the current infectious episode started more than 48 hours prior to inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Qualitative and quantitative bacterial composition of the intestinal microbiota (molecular microbiology/PCR). | From enrollment to the collection of the four swabs: 24 to 48 hours. |
Secondary
| Measure | Time frame |
|---|---|
| Mapping of E. faecalis colonization (urinary, digestive, and/or cutaneous) in patients diagnosed with E. faecalis bacteremia (EFIB); | From enrollment to the collection of the four swabs: 24 to 48 hours. |
| Genomic characterization through core genome analysis of E. faecalis strains isolated from colonization sites and from blood cultures in the same patient diagnosed with EFIB; | From enrollment to the collection of the four swabs: 24 to 48 hours. |
| Whole-genome characterization of E. faecalis strains isolated from colonization sites and those recovered from blood cultures in patients with EFIB; | From enrollment to the collection of the four swabs: 24 to 48 hours. |
| Description of potential portals of entry for enterococci at the end of hospitalization for EFIB. | From enrollment to the collection of the four swabs: 24 to 48 hours. |
Countries
France
Contacts
Primary ContactLise Laclautre
Outcome results
None listed